
    
      This observational study aims at assessing the tolerability and safety profiles of Ponatinib,
      a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is
      used during the chronic phase of the disease, according to the Italian national compassionate
      law 648/96.
    
  